Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Orea-Soufi A, Paik J, Bragança J, Donlon TA, Willcox BJ, Link W. FOXO transcription factors as therapeutic targets in human diseases. Trends Pharmacol Sci. 2022;43(12):1070-1084.

Abdallah R, Khalil A, Ghunaim S, Housheimi AE, Khalife D, Sassine D, et al. The accuracy and clinical impact of intraoperative frozen section in determining the extent of surgical intervention in patients with early stage endometrial cancer. J Obstet Gynaecol. 2022;42(5):1474-1481.

Sattler SS, Magro CM, Shapiro L, Merves JF, Levy R, Veenstra J, et al. Gastrointestinal Kohlmeier-Degos disease: a narrative review. Orphanet J Rare Dis. 2022;17(1):172.

Cambuli F, Foletto V, Alaimo A, De Felice D, Gandolfi F, Palumbieri MD, et al. Intra-epithelial non-canonical Activin A signaling safeguards prostate progenitor quiescence. EMBO Rep. 2022;23(5):e54049.

Kim SH, Roytman M, Madera G, Magge RS, Liechty B, Ramakrishna R, et al. Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET/MRI analysis in patients with meningioma. Sci Rep. 2022;12(1):9256.

Amador C, Bouska A, Wright G, Weisenburger DD, Feldman AL, Greiner TC, et al. Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. J Clin Oncol. 2022;40(36):4261-4275.

Wanna-Udom S, Luesiripong C, Sakunrangsit N, Metheepakornchai P, Intharamonthian S, Svasti S, et al. High phosphate intake induces bone loss in nephrectomized thalassemic mice. PLoS One. 2022;17(5):e0268732.

Hanel W, Lata P, Youssef Y, Tran H, Tsyba L, Sehgal L, et al. A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells. Exp Hematol Oncol. 2022;11(1):40.

Rivera-Cruz G, Boyraz B, Petrozza JC. Reply of the Authors: The Waldo of fibroids under the microscope: fumarate hydratase-deficient leiomyomata. F S Rep. 2022;3(2):174.

Tsui DC, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022;23(2):e99-e103.